Introduction
Lin-12/Notch proteins function as receptors for intracellular signals during development. Lin-12/ Notch-mediated signaling has been extensively analysed in Caenorhabditis elegans and Drosophila melanogaster and its molecular features are conserved in vertebrates (reviewed in Weinmaster, 1997; Greenwald, 1998) . The Notch proteins are large with molecular weights of approximately 300 000D. The extracellular domain of the receptor is composed of epidermal growth factor-like repeats as well as three repeats designated Lin-12/Notch or LNR repeats ( Figure 1a) . Further, the intracellular domain of Notch contains six tandem copies of an ankyrin-like motif (CDC10/ANK) as well as a PEST domain. This latter domain is thought to play a role in protein stability. The fulllength Notch receptor undergoes a proteolytic cleavage event upon ligand binding which potentiates the relocation of its intracellular domain to the nucleus (Lieber et al., 1993; Struhl et al., 1993; Kopan et al., 1994 Kopan et al., , 1996 Struhl and Adachi, 1998) .
Forms of the Notch receptor which lack most or all of the extracellular domain, or which contain selective point mutations in the extracellular domain, are constitutively active (Figure 1b ± d) . In these mutated forms, the intracellular domain constitutively localizes to the nucleus. These`activated' forms have been implicated in stochastic tumorigenesis, suggesting the involvement of collaborating oncogenes (Ellisen et al., 1991; Jhappan et al., 1992; Fortini et al., 1993; Lieber et al., 1993; Struhl et al., 1993; Kopan et al., 1994; Pear et al., 1996; Capobianco et al., 1997) . Consistent with this view, two oncogenic proteins, c-Myc and E1A, have been shown to act in concert with activated forms of Notch. Indeed, E1A was found to be necessary for the transformation of primary rat kidney cells by activated-Notch1 (Capobianco et al., 1997) . In addition, Notch1 is found as a frequent proviral insertion site in thymomas of MMTV-myc transgenic mice (Girard et al., 1996) . The potential collaboration of the myc and E1A oncogenes with other Notch family members and the possible involvement of other signal transduction pathways in Notch-mediated neoplasms is not presently known, but remains an important question.
The involvement of multiple signaling pathways and proteins in the transformation of mammary tissue has been suggested by the elevated expression of signaling components and activity in breast carcinoma as compared to normal breast tissue. Examples of such activated elements are Cyclin D1, and protein kinase C (PKC) (Tanyi et al., 1999; Platet et al., 1998) . In addition, two branches of the Ras pathway have been implicated in the transformation process. One, the Erk/ MAP kinase signaling pathway, is involved in cell growth. Elevated levels of the active, phosphorylated form of Erk have been found in cancerous breast tissue as compared to normal breast tissue. In addition, a constitutively active Erk has been implicated in the transformation process (Hennipman et al., 1989; Jacobs and Rubsamen, 1983; Ottenho-Kal et al., 1992; Graus-Porta et al., 1995; Davidson and Kennedy, 1996) . The second branch, the PI3-kinase pathway, is involved in cell survival (through phosphorylation of AKT) and in the cellular response to growth factors. Inappropriate cell survival has also been implicated in cellular transformation (reviewed in Reed, 1999) .
The ability of the Notch and Ras signaling pathways to cooperate has been further suggested by genetic interactions of the Canoe protein with certain Notch alleles, and Canoe's physical interaction with the Ras protein (Miyamoto et al., 1995; Matsuo et al., 1997) . The Canoe gene encodes a novel protein containing a GLGF/DHR motif which is conserved in the Disc's large and Dishevelled protein families (Kuriyama et al., 1996) . In addition, genetic interactions of the EGF receptor and the Groucho protein (thought to be a necessary component of the Notch downstream signaling pathway) suggests a role for EGF in stimulating Notch signals (Price et al., 1997) .
Most work to date, however, supports a mutually exclusive role for Ras and Notch signaling within the same cell (Beitel et al., 1995; Miller and Cagan, 1998; Ordentlich et al., 1998) . For example, evidence from C. elegans suggests that active signaling by Ras may transcriptionally repress the expression of the Notch receptor (Lin-12) in a cell autonomous manner, while upregulating its ligand Delta (Lag-2) (Wilkinson and Greenwald, 1995; Levitan and Greenwald, 1998) . Transcriptional feedback loops, in addition to post-translational modi®cations, could provide mechanisms by which cells prevent the inappropriate activation of two signaling pathways at the same time.
To understand the role that these pathways play in oncogenesis, we show here that tumor cell lines derived from transgenic animals expressing activated-Notch4 unexpectedly require active signaling from the Ras pathway for anchorage-independent growth. These same cell lines, however, do not require the Src-related kinases Fyn or Lyc, or protein kinase C and A for growth. Consistent with these ®ndings, primary tumors from activated-Notch4 transgenic animals contain active forms of Mek, and the PI-3 kinase target, AKT. In addition, pools of Notch tumor cells transfected with a dominant/negative form of Mek or the p85 regulatory subunit of PI-3 kinase are inhibited in their anchorage-independent growth in soft agar assays. Similarly, pools of Notch tumor cells overexpressing a dominant negative Ras are repressed in their ability to form tumors in nude mice. These results suggest a synergistic relationship between the Notch and Ras signal transduction pathways during the process of Notch initiated oncogenesis, a relationship that may have therapeutic implications.
Results
Notch tumor cell lines do not require PKA, PKC or Srclike kinase activity for anchorage independent growth Our laboratory has previously utilized a battery of chemical inhibitors to investigate the signal transduction pathway speci®city of Ras-, Neu-, Myc-, TGFa-, and heregulin/NDF-initiated tumorigenesis (Amundadottir and Leder, 1998) . We now use this approach to identify pathways that are required for Notch4-induced-tumorigenesis. Notch4 tumor cell lines display rapid growth in soft agar assays with the ®rst colonies forming within 3 ± 4 days after plating. In addition, Notch4 tumor cell lines grow with a very high eciency in soft agar (data not shown). Therefore, Notch4 tumor cell lines were grown in the presence or absence of chemical inhibitors of PKC, PKA and Srclike kinases, and assayed for their ability to form colonies in soft agar. At least two independently derived Notch4 cell lines which were expressing activated Notch4 protein, were tested and behaved in similar manner. Protein kinase C (PKC) proteins are a family of closely related isoenzymes that are crucial in signal transduction cascades that regulate the growth and dierentiation of many cell types (Nishizuka, 1986 (Nishizuka, , 1988 . In order to inhibit PKC activity, we utilized a staurosporine analogue, bisindolymaleimide (Bis) (GF109203X), as well as the chemical inhibitors, H7 and Ucn-01. Bis is a selective inhibitor for PKC (isoforms alpha, beta1, beta2 and gamma, as well as novel PKCs, see Materials and methods for IC 50 ). H7 and Ucn-01 strongly inhibit PKC activity, but also inhibit other protein kinases such as PKA (Toullec et al., 1991; Takahashi et al., 1987; Tamaoki and Nakano, 1990) . Previously these inhibitors, Bis, H7 and Ucn-01 (at the concentrations utilized here) have been tested against other kinases such as Erk/MAP kinase, JNK/SAP kinase, Fyn and Lck in mammary tumor cell lines, and did not inhibit any of these kinases at the concentrations utilized here (Amundadottir and Leder, 1998) . Results from anchorageindependent growth assays with these three inhibitors reveal no constraints on the growth of Notch tumor cell lines at the indicated concentrations (Figure 2a ± c and data not shown). These results suggest that tumor cell lines from activated Notch4-initiated tumors do not require PKC or PKA for their growth in soft agar. This result is interesting in light of our previous data in which H7 at identical concentrations was shown to be an extremely potent inhibitor of the anchorage independent growth of tumor cell lines initiated by cmyc, TGFa, neu, v-Ha-ras and heregulin. It suggests that Notch tumors have properties that dier from these other oncogenic cell types (Amundadottir and Leder, 1998) .
The non-receptor tyrosine kinase, Src, and its related kinases, Yes, Fyn, and Lck, have been implicated in cytoskeletal rearrangements, cellular proliferation and dierentiation. We tested the requirement for the Srcrelated proteins Fyn and Lck for anchorage-independent growth of activated-Notch4 tumor cell lines using the chemical inhibitor PP1. PP1 inhibits Fyn and Lck activity at concentrations much lower than those required to inhibit other known kinases (IC 50 values for Fyn and Lck are 6 and 5 nM, respectively) (Hanke et al., 1996) . At the concentrations used here, PP1 has been shown to inhibit Fyn and Lck in mammary cell lines while having no eect on PI-3 kinase, Erk/MAP kinase or Jnk/SAP kinase (Amundadottir and Leder, 1998). As shown in Figure 2d , PP1 does not inhibit the growth of Notch4 tumor cell lines in soft agar assays. Surprisingly, the Notch4 tumor cell lines showed a reproducible increase in size in the presence of PP1, but not the number of colonies in soft agar. These results suggest that the Src-related kinases Fyn and Lck are not required for the anchorage-independent growth of Notch tumor cell lines, but might in fact normally inhibit colony growth. In addition, of the other cell lines (c-myc, Tgf-alpha, Neu, heregulin and v-HA-Ras) which we had previously tested with the drug PP1, only the v-Ha-Ras cell lines, like the Notch4 cell lines tested here, showed a similar increase in soft agar colony size (Amundadottir and Leder, 1998 and this paper). This result is intriguing and suggests that Notch4 and Ras tumor cell lines might share some similar properties.
Notch4 tumor cell lines require the Erk/MAP kinase pathway and PI-3 kinase activity for anchorage-independent growth
The similarity of response of the Notch4 and Ras tumor cell lines to the Src kinase inhibitors led us to investigate potential roles of the Ras pathway in Notch4 tumor cell line growth. Previous genetic evidence in Drosophila, and C. elegans, had suggested a role for the Ras pathway in inhibition or stimulation of Notch signals. (Miyamoto et al., 1995; Sundaram and Han, 1996; Matsuo et al., 1997; Price et al., 1997) . Therefore, we asked whether the Ras signal transduction pathway was involved in the anchorage-independent growth of Notch tumor cell lines by utilizing the pharmacological agents PD098059 (PD) and LY294002 (LY). PD reversibly inhibits Mek activity towards Erk1 and Erk2 with an IC 50 value of about 10 M. At this concentration, PD has no eect on any other known kinases (Dudley et al., 1995) . Indeed, PD has been shown to be speci®c at this concentration in both NIH3T3 and mammary tumor cell lines (Amundadottir and Leder, 1998) .
To investigate the involvement of the Ras pathway in Notch tumorigenesis, Notch tumor cells were plated in soft agar along with the Mek inhibitor PD at 10 or 30 M and scored for colony formation (Figure 2e ,f, respectively). As shown, the Notch tumor cells were repressed in their growth by the inhibitor PD in a dose dependent fashion. The overall number of colonies and the size of the colonies in the presence of increased concentration of PD was signi®cantly smaller. This result suggests that Mek activity is crucial for the anchorage-independent growth of Notch4 tumors and implicates Ras-dependent signaling in Notch4 tumor growth.
We next analysed the PI-3 kinase branch of the Ras pathway to examine other potential roles of Ras in Notch4 tumor growth. We utilized the selective PI-3 kinase inhibitor LY to assess the requirement of PI-3 kinase activity for the anchorage-independent growth of Notch4 tumor cell lines. This compound selectively and reversibly inhibits PI-3 kinase activity by competing with ATP for its binding site. No other kinases (at the concentrations utilized here, 3 ± 10 mM) have been found to be inhibited by LY294002 (Vlahos et al., 1994) which has been shown to inhibit P13-kinase activity, but not Erk/Map kinase, Jnk/Sap kinase, Fyn or Lck activity in multiple mammary cell lines (Amundadottir and Leder, 1998) . As shown in Figure  2g , LY inhibited the anchorage-independent growth of Notch tumor cell lines aecting the size and the overall number of colonies. This result, combined with the PD result above, implies that Notch tumor cell lines utilize both the growth (Mek) and survival (PI-3 kinase) branches of the Ras signal transduction pathway. Since the drugs PD and Ly each inhibited the anchorageindependent growth of Notch4 cells, we hypothesized that the combination of the two inhibitors might have a synergistic eect.
To test the above notion, Notch4 tumor cells were treated with both PD and LY, and assayed for their ability to form colonies in soft agar. As shown in Figure 2h , the combination of PD and LY abolished the growth of Notch4 tumor cell lines in soft agar. This result suggests that Notch4 tumor cell lines need both branches of the Ras pathway for growth. To rule out the possibility that the combination of PD and LY is toxic to the cells (thus explaining their lack of anchorage-independent growth), we withdrew the drugs to distinguish between growth inhibition and toxicity. Both PD and LY are labile, reversible inhibitors. Cells were treated with media lacking drug over a period of 3 days, thereby diluting any drug present. As shown in Figure 2i , after 3 days of drug withdrawal, the cell lines which had failed to grow in the presence of PD and LY grew to a similar size and number as the controls. This result indicates that the combination of PD and LY inhibits the anchorage-independent growth of Notch4 tumor cell lines in a reversible fashion, and is not toxic.
Overexpression of a dominant negative Mek or PI-3 kinase inhibits the anchorage-independent growth of Notch tumor cell lines PD and LY have been shown to be highly speci®c for Mek and PI3-kinase, however, it is possible that they interfere with other pathways for which they have not been tested. To address this concern, we employed a genetic strategy utilizing dominant negative versions of Mek, PI3-kinase and Ras. Notch4 tumor derived cell lines were transfected with Cmv-Neo (vector control),
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Cmv-DnMek (a dominant negative Mek), and Cmvp85 (the regulatory subunit of PI-3 kinase), and selected for pools of cells with stably integrated copies of each construct. These pools were then plated in our soft agar assay and scored for anchorage-independent growth. Consistent with our drug inhibitor studies, the cells expressing Cmv-DnMek or Cmv-p85 were inhibited in their anchorage-independent growth as compared to cells with the vector control ( Figure  3a ± d) . Cmv-DnMek and Cmv-p85 were slightly less eective in inhibiting Notch tumor cell growth than the Mek and PI-3 compound inhibitors. This lower eciency most likely re¯ects a variable expression of these constructs in individual expressing clones. These results show that direct molecular interference of the Mek and PI-3 kinase branches of the Ras pathway inhibits the anchorage-independent growth of Notch4 tumor cells.
The combination of PD and LY (and their subsequent disruption of Mek and PI-3 kinase activity) exhibited the greatest inhibition of anchorage-independent growth of Notch4 tumor cell lines. We, therefore, hypothesized that overexpression of a DnRas (which theoretically should eect both Mek and PI-3 kinase activity) should be a strong inhibitor of Notch4 tumor cell lines, mimicking the eects of the PD/Ly drug combination. Notch4 tumor cell lines expressing either Cmv-Neo vector control, or Cmv-DnRas, were selected and pooled. The selected pools were injected subcutaneously into nude mice and assayed for their ability to form tumors. As shown in Figure 4a , tumors arising from Notch4 tumor cells expressing CmvDnRas grew signi®cantly more slowly in NIH Hfh11 (nude) mice than cells selected to contain stable copies of the vector control. Tumor cell lines containing stable copies of Cmv-p85 or Cmv-DnMek also grew more slowly as transplants than Cmv-vector alone (data not shown).
Primary Notch tumors have active Mek and Akt
As the results above indicate, the Ras pathway is necessary for the anchorage-independent growth of Notch tumor cell lines and for tumor formation in nude mice. Nonetheless, we wanted to be con®dent that activation of the Ras pathway in Notch tumor cell lines is not a by-product of the cell culturing process. To this end, we examined Mek and PI-3 kinase activity in primary tumors initiated by activated-Notch4. This was done using phospho-speci®c antibodies to Akt (a substrate of active PI-3 kinase) and to Mek which detect the active, phosphorylated forms of these kinases. As shown in Figure 5a ,b, 3/3 primary Notch tumors contained active forms of Akt and Mek, indicating that these two arms of the Ras pathway are active in primary Notch tumors. Taken together, these results indicate that activated-Notch4 collaborates with active signals from the Ras pathway during Notch4-initiated tumor growth.
Discussion
We have utilized a panel of small molecular weight inhibitors that target various signal transduction pathways to analyse the contribution of these pathways to the anchorage-independent growth of Notch4-initiated tumors. Surprisingly, our results demonstrate that the Ras pathway, including its downstream signaling Figure 2) components, PI-3 kinase and Mek, are active in primary Notch4-initiated tumors and are crucial to the anchorage-independent growth of Notch4-initiated tumor cell lines. This is surprising because most work to date supports a mutually exclusive role for Ras and Notch signaling in the same cell. The conditions under which Notch-initiated tumors form may, however, be dierent from the cellular environment from which the earlier results were obtained. For example, in these experiments, as in the case of Notch1-mediated lymphoma in human patients (where a truncated Notch1 protein is expressed from the TCR promoter due to a translocation), the activated Notch receptor is not expressed from its endogenous promoter. Thus, Notch expression may be insensitive to transcriptional feedback loops which would normally control its proper down-regulation. The ability of cells with high Ras signaling activity to down-regulate Notch signals in this case would be compromised and this may be responsible for the transformation process. Disruption of normal feedback loops at the transcriptional and post-transcriptional level, while often overlooked, might contribute to cellular transformation.
While we found that Notch4-and v-Ha-Ras-initiated tumor cell lines behave similarly in response to most chemicals, they do not respond identically. Speci®cally, while v-Ha-Ras tumor cell lines (and indeed most other oncogene-initiated cell lines tested) were inhibited in their soft agar growth by inhibitors of Protein kinase C and Protein kinase A (Bis, UCN-01 or H7) (Amundadottir and Leder, 1998), Notch tumors were not. In addition, while mouse mammary glands overexpressing either Notch or Ras fail to develop properly, there are phenotypic and histological dierences in the type of growth that is seen (data not shown). Together, these results indicate that Notch-initiated tumors have a unique signal transduction pro®le.
We have also found that the growth of Notch initiated cell lines, like v-Ha-Ras-initiated tumors, may be increased by the Fyn and Lck inhibitor compound, PP1. These results suggest additional overlapping signaling pathway usage by these tumor cell types. In cases where the oncogenic event is Notch-or Rasinitiated, inhibitors of the Src-kinases and their associated signaling pathways may actually increase tumor size in aected patients.
Finally, we noticed that injection of the Notch4-initiated tumor cell lines often resulted in the formation of massive hematomas (8/8 injected animals), that lead to the death of the injected animals ( Figure 4 and data not shown). It is intriguing to note that the expression pattern of murine Notch4 is endothelial cell speci®c and that mutated forms of the Notch3 receptor have been implicated in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) who suer recurrent stroke and associated vascular disease (Uyttendaele et al., 1996) ; reviewed in Joutel and Tournier-Lasserve, 1998) .
In summary, this work supports a model in which tumor types are unique and tumor growth responds to a combinatorial code of signaling pathways. This code depends to some degree upon the initiating oncogene. The ability to correlate initiating oncogenes with all of their complex array of interacting pathways, should play a role in developing tumor-speci®c therapy.
Materials and methods

Cell lines and tumors
Mouse mammary gland cell lines were derived from mammary and salivary tumors arising in transgenic mice which express an activated form of Notch4 from the mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter/enhancer, (exactly as in Jhappan et al., 1992) . The following Notch derived tumor cell lines were used in anchorage-independent assays (5505 ± breast, 5535 ± salivary, 5923 ± breast). The cells were routinely grown in 10% bovine calf serum (BCS, Gibco-BRL, Gaithersburg, MD, USA) 4 mM glutamine (Bio-Whittaker, MD, USA), penicillin (50 U/ml) and streptomycin (50 mg/ml) (Sigma, St. Louis, MO, USA).
Anchorage-independence assays 500, 1000 or 5000 cells were suspended in 0.36% bactoagar (Difco, Detroit, MI, USA) and seeded into 35 mm dishes over a 0.6% agar base layer in DMEM plus 10% BCS containing the appropriate amount of pharmaceutical reagent. The plates were fed daily with 300 microliters of media to which the treatments had also been added as indicated. After 3 ± 5 days the entire plate was photographed at the same magni®cation under a dissecting microscope and the number of colonies and their relevant size were noted. Each experiment was carried out in triplicate and repeated at least two times. Treatments were PD098059 10 ± 30 micromolar (a generous gift of Dr David Dudley, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co, Ann Arbor, MI, USA), LY294002 3 ± 10 micromolar (Calbiochem, La Jolla, CA, USA), H7 40 micromolar (Seikagaku America, Ijamsville, MD, USA) and PP1 at 50 nanomolar (Calbiochem). All treatments were given in 10% BCS. Vehicle (1 : 1000) DMSO was added to control dishes. These studies were done at the same concentrations, with the same lot of chemicals, with the same protocols and in the same time frame as a previous investigation by our laboratory (Amundadottir and Leder, 1998) which analysed tumors initiated by c-Myc, v-Ha-Ras, heregulin/NDF, neu and TGFa, thereby allowing for a direct comparison and discussion of the ®ndings.
Western analysis
Primary tumor tissue was analysed in RIPA buer by sonication, with the addition of complete protease inhibitor cocktail (Boehringer Mannheim). Equivalent amounts of protein (Bradford-reagent from Bio-rad) were separated in 10% SDS ± PAGE and transferred to Immobilon-P membranes (Millipore Corporation). Phospho-speci®c antibodies to AKT and MEK were purchased from New England Biolabs (Beverly, MA, USA) and were used in accordance with the manufacturer's instructions. Equivalent loading of protein was also veri®ed with Ponceau Red staining of the Western blot membranes.
Transfections and Hfh11 (nude mice) tumor assay
The Notch tumor cell line 5505 was transfected with 5 mg of Cmv-Neo (PCDNA3 Invitrogen), Cmv-DnMek (a generous gift of Susan MacDonald), Cmv-DnRas, and Cmv-p85 (a generous gift of Dr Lewis Cantley) by the calcium phosphate co-preceipitation method. Co-transfection of Cmv-Neo at a 1 : 50 dilution was utilized as necessary for selection. Selection was with G418 at 705 mg/ml for 10 days. The resultant G418 resistant colonies were pooled and utilized directly in anchorage-independent assays or injected (one million cells per injection) subcutaneously into NIH Hfh11 nude mice) (Taconic Laboratory). The injected mice were observed daily for nodule formation. Mice were injected on opposite¯anks with cells containing vector alone or cells with Cmv-DnRas. Nude mice with nodules were photographed and the nodules excised and weighed. Tumors were excised and weighed 10 days after cell injection. Longer time points became dicult to assess due to hemangioma formation.
